CYPDESIGN is dedicated to supporting your drug research and development needs by offering you stabilised, highly active cytochrome P450 (CYP) enzyme products. These products are presented in our unique Sacchrosomes™ and are stable at room temperature. This provides significant cost advantages as our products do not need to be shipped with dry-ice, or kept in cold storage before use, and they will provide you with greater convenience due to their stability at room temperature.
CYPDESIGN's products will satisfy your requirements for quality in early stage testing for new drug discovery. Our products are more active and more stable, easier to handle and more convenient to use than other commercially-available CYPs.
We also offer reliable contract research services in metabolism and toxicity testing and in biocatalysis.
CYP Design's CEO, Bill Primrose, explains the unique features of the company's CYP stabilisation technology, in a video made to support the Start-Up of the Year Award from Medilink East Midlands in June 2014
CYPDESIGN has developed a unique stabilisation process that allows CYPs, which are ordinarily extremely labile at temperatures other than -80ºC, to be maintained at room temperature, greatly increasing their convenience for the end-user. They can thus be shipped and stored without the need for a cold chain.
Significantly, for the end user, not only do our Sacchrosomes™ make for ease of use, but in use the researcher isn't constrained to work within a particular timeframe.
We can supply all of the major human drug metabolising CYPs, provided as dried down films, ready for reconstitution and immediate use. Shipped without the need for a cold chain, and with no need for low temperature storage, these are ready to use "off the shelf". And there is no need to pipette viscous, heterogeneous solutions.
Arrayed into the format of your choice, whether vials, 96- or 384-well microtitre plates, exact amounts of each CYP are aliquotted into the wells of a microtitre plate.
All CYP products contain NADPH-dependent P450 reductase, and cytochrome b5 where necessary, and are presented as lyophilised films ready for immediate reconstitution and use in your assays.
Yeast microsomes are more similar to the mammalian system than those from insect cells.
CYPDESIGN's yeast microsomes (presented in our unique Sacchrosomes™) reliably demonstrate that the yield and activity of human CYP enzymes in Sacchrosomes™ are at least comparable and often better than those from other suppliers who use insect cells or bacteria.
In the Comparative Performance section of this site you will find representative kinetic plots for nine different human CYPs, comparing the activities from CYPDESIGN's Sacchrosomes™ with those from a leading supplier's insect cell-expressed CYPs. More detailed comparisons are shown in the product data sheets accompanying each individual CYP Sacchrosome™.
CYPDESIGN has developed a unique stabilisation process that allows CYPs to be maintained at room temperature, greatly increasing their convenience for the end-user. Thus they can be shipped and stored without the need for a cold chain.
CYPDESIGN is building on the technological breakthroughs of its founder, Professor Bob Chaudhuri of De Montfort University, in the expression and stabilisation of the key family of human liver enzymes, cytochrome P450s (CYPs), responsible for the metabolism of chemicals in the body, including pharmaceuticals.
Professor Chaudhuri has developed proprietary technology for the expression of recombinant human CYPs, which are more active and more stable, cheaper to produce, and more convenient to use than other commercially-available CYPs.
CYPDESIGN's successful generic expression system allows for the production of recombinant CYPs in yeast, insect and mammalian cells. We have the ability to clone and produce a CYP from any organism (insect, parasite, fungi, plant, etc).
Our expression of human CYPs in yeast results in the production of highly active enzyme preparations presented in the form of Sacchrosomes™ (microsomes), a unique membrane system which brings together all the components necessary for activity in a convenient and highly reproducible way.
CYPDESIGN has also developed a unique stabilisation process that allows CYPs, which are ordinarily extremely labile at temperatures other than -80ºC, to be maintained at room temperature, greatly increasing their convenience for the end-user. They can thus be shipped and stored without the need for a cold chain.
CYPDESIGN's team also has considerable expertise in CYP biology and chemistry, providing the basis for new products and services, including metabolism and toxicity testing services, reagents for biocatalysis, and the potential for developing new cancer therapeutics.
CYPDESIGN make drug discovery better by providing products that have a significant impact on the timescales and costs involved in the early stages of drug discovery.
Our team is dedicated to seeing better, faster and more convenient decision-making tools available for drug discovery. Applying the technology that world-renowned expert Professor Chaudhuri and his team have been developing in the field of human CYP enzyme expression and stabilisation.
Bob is Professor of Cancer Studies at the Leicester School of Pharmacy. His background is in chemistry, molecular cell biology, molecular pharmacology and molecular toxicology. He is an expert in yeast expression systems and in the discovery of new cancer drugs.
Previously a Senior Scientist at Novartis, he was involved in the development of three marketed pharmaceuticals, and is the principal inventor on more than 20 granted patents.
With a comprehensive background in financial, corporate and business management, and a good track record as a serial entrepreneur, David joined the founders as an 'engaged investor' to manage the business of the board as Non-Executive Chairman.
A Chartered Director and Master of Business Administration, and with a wealth of knowledge, business experience and professional contacts, David's focus is to add shareholder value and to ensure good corporate governance.
Bill is a serial founder of biotechnology businesses, focussed on small molecule drug discovery and associated services. He was a co-founder of PanTherix, a University of Leicester spin-out working in anti-infectives. He founded and managed a contract chemistry company, SioKem. He was previously CEO of IntelliHep (sugar therapeutics) and, from 2007 to 2012, he was CEO of Theryte developing novel cancer drugs.
A founder of the company, Bill is Chief Executive Officer.
Paul is an entrepreneur with more than 30 years' experience in life sciences. He has co-founded and raised finance of over £30 million for 10 biotechnology companies. He is Managing Director of Ithaka Life Sciences and Executive Chairman of ProteinLogic. He was previously Executive Chairman of Psynova Neurotech.
A founding member of the company, Paul is a Non-Executive Director providing valuable industry knowledge and resources.
Derek is the founder and Managing Director of ProspectIP, an intellectual property (IP) management company. He is a proven IP and innovation practitioner with a strong entrepreneurial background and a passion for technology commercialisation. He has over 18 years' experience in technology commercialisation and has had first hand experience in starting, securing equity finance, developing and commercialising IP rich businesses.
Derek is a Non-Executive Director and also represents the interests of De Montfort University, a shareholder in the company.
Co-founder of Mercia Fund Managment and Senior Investment Manager, Tim has been involved in investment work since 1985, first with UBS Phillips and Drew and thereafter with 3i PLC, WM Enterprise and the Baring English Growth Fund.
A graduate in Mechanical Engineering from Imperial College, London, Tim also has a Masters Degree in Science Technology and Industrialisation, an MBA and is fully FCA accredited.
Tim is a Non-Executive Director and represents the interests of the Mercia Growth Fund.
CYPDESIGN is pleased to announce that it has completed a £325k seed funding round led by Gask Consulting under the Enterprise Investment Scheme (SEIS). As part of the EIS round, Mercia Fund Management also followed its earlier SEIS investment.
CYPDESIGN is delighted to announce that it has been given the Start-Up of the Year award at the Medilink East Midlands Innovation Day Business Awards in Leicester on 11th June 2014.
CYPDESIGN has been awarded a grant by the government-backed Technology Strategy Board - the UK's innovation agency - to help support the development of new products and services, based on cytochrome P450s (CYPs).
Full Press Release available
CYPDESIGN is seeking to purchase or rent a lyophiliser with temperature-controlled shelves to develop its in-house production process for the manufacture of stabilised, dry films of sensitive membrane-bound enzymes. A research laboratory-scale instrument is required at this stage.
CYPDESIGN has been awarded funding by the UK Defence Science and Technology Laboratory's (Dstl) Centre for Defence Enterprise (CDE) for research designed to validate an automated platform for the discovery of safe, effective, broad-spectrum anti-bacterial compounds.
Full Press Release Available:
CYPDESIGN is pleased to announce that it has completed a seed funding round led by Mercia Fund Management Ltd (MFM) under the Seed Enterprise Investment Scheme (SEIS). As part of the SEIS round, the founders Prof Bob Chaudhuri, Dr Bill Primrose and Dr Paul Rodgers have been joined by Mr David Gask, a leading entrepreneur, as Chairman of the Board.
Full Press Release Available:-
CYPDESIGN presented its technology in the Innovation Zone of the ELRIG DD Conference in Manchester Central. We exhibited our products for metabolism and toxicity testing in Booth IZ4.
CYPDESIGN published an article in 'Industrial Pharmacy' entitled "Stable Cytochorme P450 Enzymes for Toxicity and Metabolism Testing". See Industrial Pharmacy, June 2013, Issue 38, pages 4 - 7
CYPDESIGN presented in the 'Platform & Diagnostics' Session of the 10th Anniversary EPIC Biotechnology Conference at the King's Fund in London on Thursday 6th June 2013.
CYPDESIGN was a finalist in the Royal Society of Chemistry's Emerging Technologies Competition, held in the Chemistry Centre, Piccadilly, London on Wednesday 5th June 2013.
CYPDESIGN attended BioWales 2013 at the Wales Millennium Centre, Cardiff
CYPDESIGN exhibited its unique stabilised cytochrome P450 products in the New Technology Showcase at the ELRIG Research and Innovation meeting in Telford
CYPDESIGN is a young and vibrant biotech company headquartered in Leicester, which is developing new products and services for the global drug discovery industry. The company has developed proprietary technology for the expression of human cytochrome P450 enzymes (CYPs) in yeast, and their subsequent stabilisation, allowing transport and storage at ambient temperature.
We expect to see significant growth through a milestone driven strategy and global diversification. As we expand, we will bring on a plethora of exceptional talent to help us further extend our manufacturing and marketing capabilities. These talented people will help us to diversify our product lines, enabling us to become the global leader for CYP-based products and services.
CYPDESIGN currently has a vacancy for an experienced molecular cell biologist to be appointed as a Senior Scientist (position CDL-03). The position is available immediately.
PLEASE NOTE THAT THE DEADLINE FOR APPLICATIONS FOR THIS POSITION HAS NOW PASSED
Contact us via any of the following methods, or feel free to get in touch via this email form.
CYP Design Limited
49 Oxford Street
38 Greville Road
Phone: 01223 247468